ABVC BioPharma Reports 230% Licensing Revenue Growth and Major Asset Expansion in Q3 2025

ABVC BioPharma, Inc. reported substantial financial growth for the third quarter of 2025, with licensing revenue increasing approximately 230% year-over-year to $1.28 million compared to $0.39 million in the same period of 2024. The clinical-stage biopharmaceutical company also demonstrated significant asset expansion, with total assets growing 181% to $21.18 million as of September 30, 2025, up from $7.54 million at the end of 2024. This financial performance reflects the company's strategic execution in developing therapeutic solutions for central nervous system, ophthalmology, and oncology/hematology indications.

The company's property and equipment showed remarkable growth, increasing approximately 2,100% to $12.06 million from $0.51 million at the end of 2024. This substantial expansion resulted from strategic real-asset investments in Taiwan, where the company completed two land acquisitions totaling approximately $11 million during the third quarter. AiBtl BioPharma Inc. acquired property in Puli, Nantou for $7.67 million to develop a plant factory for botanical raw materials and new drug substance research, while ABVC BioPharma, Inc. invested $3.3 million in Longtan, Taoyuan for agricultural research and development and API cultivation.

These investments are part of ABVC's broader strategy to strengthen its Asia-based production and research capabilities, complementing the planned Vitargus® GMP manufacturing facility. The company maintains a global dual-core operational structure, with Silicon Valley focusing on innovation and clinical development through its BioKey platform, while Taiwan supports manufacturing and development activities. This approach allows ABVC to leverage regional strengths while maintaining an asset-light business model centered on licensing, partnerships, and collaborative development.

ABVC continues to advance multiple licensing agreements covering its CNS, ophthalmology, and oncology pipelines, each providing potential future milestone and royalty income based on development and commercialization progress. The company's pipeline includes six drugs and one medical device under development, with drug products utilizing in-licensed technology from research institutions including Stanford University, University of California at San Francisco, and Cedars-Sinai Medical Center. For Vitargus®, the company intends to conduct pivotal clinical trials through global partnerships.

Dr. Uttam Patil, ABVC's Chief Executive Officer, stated that the third-quarter results reflect continued progress in both licensing revenue and asset development activities, emphasizing the company's focus on executing strategic priorities to create sustainable long-term value for shareholders. The company's recent investments in physical assets in Taiwan are expected to enhance future research and manufacturing capacity while supporting the advancement of key pipeline assets and exploration of additional partnerships. More detailed information about the company and risk factors is available in the company's filings with the Securities and Exchange Commission at http://www.sec.gov.